Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

nanotech x-ray tube

Cel

Luxbright develops next generation x-ray tube technology. The products we are developing for this project include a nano-material cold cathode x-ray tube and advance tube innovations (other internal components). We have applied for patents in key areas and we plan to sell it to medical imaging device manufacturers with the end consumer being hospitals and medical facilities.

X-ray tubes are a component within medical imaging devices (x-ray machines). The innovations are derived from a nano-material structure which enables x-rays to be produced through a process called field emission. The other tube technologies allow for other improvements in imaging. For this project, the overall objective (Phase 2) is to reach first sales of our tube technology inclusive of developing a pilot system. First sales will likely be to a mini C-arm (a type of x-ray machine) system manufacturer. Within Phase 1 of this, the objective is to complete feasibility assessments for reaching first sales of x-ray tubes.

The specific objectives of the feasibility assessments are as follows: Develop Internal Organization, Market Study, Innovation Strategy Development, IP Management Strategy, Partner Contracting, Develop Business Model and Risk Assessment.

The business opportunity stems from the desired solutions to social problems, economic inefficiencies, and technical inefficiencies of today’s conventional x-ray tubes. Conventional tubes generate x-rays using a thermionic mechanism with numerous pitfalls which can be improved.

The effects of incorporating the nanoscale structures in this product result in x-ray tubes which generate social value (through safer treatment experiences) and economic value (by allowing hospitals to treat more patients per day in tandem with increased patient satisfaction). Specifically, the product offers 1000x faster rising time, is safer for patients and hospital staff (reduced radiation), offers increased mobility, allows hospitals to treat more patients per day, and increases energy efficiency.

Zaproszenie do składania wniosków

H2020-SMEInst-2014-2015

Zobacz inne projekty w ramach tego zaproszenia

Szczegółowe działanie

H2020-SMEINST-1-2015

Koordynator

LUXBRIGHT AB
Wkład UE netto
€ 50 000,00
Adres
ARVID WALLGRENS BACKE 20
413 46 GOTEBORG
Szwecja

Zobacz na mapie

MŚP

Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.

Tak
Region
Södra Sverige Västsverige Västra Götalands län
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Linki
Koszt całkowity
€ 71 429,00